02/10/2026
👀👀👀
A small but intriguing transplant study is exploring a new way to prevent rejection without the usual daily high toxicity drugs.
In a phase 2a trial published in the American Journal of Transplantation and reported by Medscape, researchers tested a dual biologic regimen of dazodalibep plus belatacept as the main long term anti rejection therapy after kidney transplant. The goal is to reduce reliance on calcineurin inhibitors and steroids, which work well but carry long term risks and side effects.
In 23 kidney transplant recipients, the regimen was generally safe, preserved kidney function, and showed no cases of antibody mediated rejection. Even when rejection occurred, kidney function recovered after standard rescue treatment. Patient and graft survival were 100 percent at one year.
This is early phase research and the study was small, but it points toward a future where transplant patients may rely on more targeted biologic therapies with fewer toxic effects and potentially better long term adherence.
Kidney transplantation science keeps moving forward. 💚
